ACT 2001

Drug Profile

ACT 2001

Alternative Names: ACT2001; CryoIT; Dendritic cell based cryoimmunotherapy

Latest Information Update: 27 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Haakon Ragde Foundation
  • Developer Alden Cancer Therapy II; Haakon Ragde Foundation; Norwegian Radium Hospital
  • Class Antineoplastics; Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 01 May 2015 Phase-I clinical trials in Prostate cancer (Combination therapy, Metastatic disease, Hormone refractory ) in Norway (Intratumoral) (NCT02423928)
  • 15 Apr 2015 Alden Cancer Therapy II plans a phase I trial for Prostate Cancer (Metastatic disease) in Norway
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top